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Background
The Global Allergy and Asthma European Network
(GA2LEN) is a network of the leading European allergy
clinical and research facilities and the GA2LEN Sinusitis
Cohort is a database within this network. The aim of
this cohort is to intensify research on rhinosinusitis
pheno- and endotypes, thus differentiating chronic rhi-
nosinusitis (CRS) into smaller disease entities based on
clinical, biological, and patient-reported outcomes.
Methods
Patients (N = 869) from 9 participating outpatient ENT
clinics recruited to participate in this cross-sectional, mul-
ticentre cohort study were assigned to 3 groups: CRS with
nasal polyps (CRSwNP) and CRS without nasal polyps
(CRSsNP), both diagnosed using EPOS 2012 guidelines;
and control defined as an unmatched cohort of patients
undergoing nasal turbinate surgery with or without allergy
symptoms. Patient subgroups were compared by clinician
reported, patient reported, imaging, endoscopy, lung func-
tion, and biomarker outcomes.
Results
Overall, 51.2%, 27.3%, and 21.5% of patients were in the
CRSwNP, CRSsNP, and control groups, respectively.
Across groups, mean age was 42.1 years (range 15–
76 years), 55.0% were male, and 95.5% were Caucasian.
Comorbid allergic rhinitis was diagnosed in 33.2%, 29.0%,
and 23.8% of patients in the CRSwNP, CRSsNP, and con-
trol groups, respectively. Of all patients, 33.2% had comor-
bid asthma, which was significantly (p < 0.0001) more
frequent in the CRSwNP (49.6%) than CRSsNP (20.2%)
group. CRSwNP patients reported late age of onset for
asthma, whereas CRSsNP patients reported early age of
onset. Among CRSwNP and CRSsNP patients who did not
report asthma, 59.8% and 41.9%, respectively, had an
FEV1/FVC ratio of ≤ 80% (p = 0.063). Contact allergy was
present significantly more often in CRSsNP than CRSwNP
patients (15.1% vs 5.2%; p = 0.0001). Overall, 4.4% of all
patients reported aspirin intolerance, which was signifi-
cantly more frequent in CRSwNP vs CRSsNP patients
(7.4% vs 1.3%; p < 0.0001); among these CRSwNP patients,
90.9% had asthma, forming the Aspirin Exacerbated
Respiratory Disease (AERD) subgroup. A significantly
higher number of CRSwNP patients reported previous sur-
gery vs CRSsNP patients (45.9% vs 22.7%; p < 0.0001).
Discussion
The GA2LEN Sinusitis cohort was not intended to be
population representative; however, it is a large cohort
of patients recruited throughout Europe with clinical,
biomarker, as well as patient-reported outcomes.
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